Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRA: AZD5305 Monotherapy and Combinations in Advanced Solid Malignancies
NCT04644068Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- May 2027
- Countries
- 14
01
Overview
A Phase 2 trial of saruparib in ovarian cancer, breast cancer, pancreatic cancer (PC), prostate cancer (PCa), non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2020; status: active, not recruiting.
02
Drugs
saruparib
03
Conditions
ovarian cancerbreast cancerpancreatic cancer (PC)prostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04644068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644068.